Servicio Hematología, Complexo Hospitalario Universitario A Coruña, INIBIC, A Coruña.
Banc de Sang iTeixits.
Blood Coagul Fibrinolysis. 2022 Jan 1;33(Suppl 1):S12-S14. doi: 10.1097/MBC.0000000000001093.
Von Willebrand disease (VWD) is the most frequent inherited bleeding disorder caused by quantitative or qualitative defects of von Willebrand factor (VWF). This protein far from simplicity constitutes a very complex molecular model, remaining unravelled yet many aspects of it, even though the VWF gene (VWF) was cloned already in 1985 and the structure of VWF well defined. VWD diagnosis is difficult to achieve in a significant proportion of patients due to both disease heterogeneity and limitations in existing test processes. The cornerstone of diagnosis relies on interpretation of VWF test results, the presence of clinical manifestations of bleeding, especially mucocutaneous, and (in most cases) a positive family history. However, even with a significant bleeding history, a family history may not be positive due to factors of incomplete penetrance and variable expressivity that affect genetic changes. The laboratory diagnosis of VWD can be difficult, as the disease is heterogeneous and an array of assays is required to describe the phenotype. Basic classification of quantitative (type 1 and 3) and qualitative (type 2 variants) VWD requires determination of VWF antigenic (VWF:Ag) levels and assaying of VWF ristocetin cofactor (VWF:RCo) activity. The latter is required for identifying and subtyping VWD, but the assay is poorly standardized. For that reason, novel VWF activity assays have been developed awaiting more extensive comparison data between different methodologies and requiring validation on larger patient series. The qualitative type 2 VWF deficiency can be further divided into four different subtypes (A, B, M and N) using specific assays that measure other activities or the size distribution of VWF multimers. However, frequently, it may be difficult to correctly classify the VWD phenotype, and genetic analysis is through mutation identification may provide a tool to clarify the disorder.
血管性血友病(VWD)是最常见的遗传性出血性疾病,由血管性血友病因子(VWF)的数量或质量缺陷引起。这种蛋白质远非简单,它构成了一个非常复杂的分子模型,尽管 VWF 基因(VWF)已于 1985 年被克隆,VWF 的结构也已被很好地定义,但仍有许多方面尚未被揭示。由于疾病的异质性和现有检测过程的局限性,VWD 在很大一部分患者中的诊断都很困难。诊断的基石依赖于 VWF 检测结果的解释、出血的临床表现,尤其是黏膜皮肤,以及(在大多数情况下)阳性家族史。然而,即使有明显的出血史,由于遗传改变的不完全外显率和可变性表达,家族史也可能为阳性。VWD 的实验室诊断可能很困难,因为该疾病具有异质性,需要一系列检测来描述表型。定量(1 型和 3 型)和定性(2 型变异)VWD 的基本分类需要测定 VWF 抗原(VWF:Ag)水平和测定 VWF 瑞斯托菌素辅因子(VWF:RCo)活性。后者是识别和亚分型 VWD 所必需的,但该检测方法尚未标准化。因此,已经开发了新的 VWF 活性检测方法,以等待不同方法之间更广泛的比较数据,并需要在更大的患者系列中进行验证。定性 2 型 VWF 缺乏症可以使用测量 VWF 多聚体其他活性或大小分布的特定检测方法进一步分为四个不同亚型(A、B、M 和 N)。然而,通常情况下,可能难以正确分类 VWD 表型,而基因突变分析可能提供一种工具来阐明该疾病。